Theodore R. Schroeder - 06 Jan 2023 Form 4 Insider Report for Nabriva Therapeutics plc

Role
Chief Executive Officer, Director
Signature
/s/ J. Christopher Naftzger, by power of attorney
Issuer symbol
N/A
Transactions as of
06 Jan 2023
Net transactions value
-$14.3
Form type
4
Filing time
10 Jan 2023, 16:56:53 UTC
Previous filing
04 Jan 2023
Next filing
31 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBRV Ordinary Shares Tax liability $14.3 -11 -0.09% $1.30 12,420 06 Jan 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.